Anebulo Pharmaceuticals, Inc. (ANEB)
NASDAQ: ANEB · Real-Time Price · USD
1.260
-0.140 (-10.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
Company Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States.
Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity.
The company was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | May 7, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Richard Cunningham |
Contact Details
Address: 1017 Ranch Road 620 South, Suite 107 Lakeway, Texas 78734 United States | |
| Phone | 512 598 0931 |
| Website | anebulo.com |
Stock Details
| Ticker Symbol | ANEB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 0001815974 |
| CUSIP Number | 034569103 |
| ISIN Number | US0345691036 |
| Employer ID | 85-1170950 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Anthony Cunningham | Chief Executive Officer and Director |
| Dr. Joseph F. Lawler M.D., Ph.D. | Founder and Chairman |
| Daniel V. George | Principal Accounting Officer, Acting Chief Financial Officer and Secretary |
| Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 20, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | 10-Q | Quarterly Report |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 12, 2025 | 8-K | Current Report |
| Dec 31, 2024 | D | Notice of Exempt Offering of Securities |
| Dec 26, 2024 | SCHEDULE 13D/A | Filing |
| Dec 23, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |